• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-L1 通过激活 PI3K/AKT 通路诱导鼻咽癌细胞发生上皮-间充质转化。

PD-L1 Induces Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway.

机构信息

Department of Radiation and Medical Oncology, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, P.R. China.

Department of Radiation Oncology, Xiang'an Hospital of Xiamen University, Fujian, P.R. China.

出版信息

Oncol Res. 2019 Jul 12;27(7):801-807. doi: 10.3727/096504018X15446984186056. Epub 2019 Apr 12.

DOI:10.3727/096504018X15446984186056
PMID:30982497
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7848446/
Abstract

Nasopharyngeal cancer (NPC) is a malignant epithelial carcinoma of the head and neck. Cancer therapy targeting programmed cell death protein-1 (PD-1) or programmed death ligand-1 (PD-L1) is revolutionary. However, the tumorigenic mechanism of PD-L1 is not yet clear in NPC. Here we demonstrated an oncogenic role of PD-L1 via activating PI3K/AKT in NPC cells. PD-L1 overexpression was frequently detected in NPC biopsies and cell lines by qRT-PCR. PD-L1 overexpression and knockdown demonstrated that PD-L1 promoted NPC cell invasion and metastasis in vitro and in vivo. Mechanistically, PD-L1 prominently activated the epithelial-mesenchymal transition (EMT) process in a PI3K/AKT-dependent manner. Taken together, we found that PD-L1 overexpression confers NPC cell malignancy and aggressiveness via activating the downstream PI3K/AKT signaling. Thus, these results provide a basis for diagnosis and treatment of NPC.

摘要

鼻咽癌(NPC)是头颈部的一种恶性上皮癌。针对程序性细胞死亡蛋白-1(PD-1)或程序性死亡配体-1(PD-L1)的癌症治疗具有革命性意义。然而,PD-L1 在 NPC 中的致癌机制尚不清楚。在这里,我们通过在 NPC 细胞中激活 PI3K/AKT 来证明 PD-L1 的致癌作用。qRT-PCR 检测到 NPC 活检和细胞系中 PD-L1 过表达频繁。PD-L1 过表达和敲低证明 PD-L1 促进 NPC 细胞体外和体内侵袭和转移。在机制上,PD-L1 以 PI3K/AKT 依赖性方式显著激活上皮-间充质转化(EMT)过程。总之,我们发现 PD-L1 过表达通过激活下游的 PI3K/AKT 信号赋予 NPC 细胞恶性和侵袭性。因此,这些结果为 NPC 的诊断和治疗提供了依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b187/7848446/1c38d1b96c76/OR-27-801-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b187/7848446/c228b209ee70/OR-27-801-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b187/7848446/096bf6a73590/OR-27-801-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b187/7848446/b36ba893c189/OR-27-801-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b187/7848446/1c38d1b96c76/OR-27-801-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b187/7848446/c228b209ee70/OR-27-801-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b187/7848446/096bf6a73590/OR-27-801-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b187/7848446/b36ba893c189/OR-27-801-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b187/7848446/1c38d1b96c76/OR-27-801-g004.jpg

相似文献

1
PD-L1 Induces Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway.PD-L1 通过激活 PI3K/AKT 通路诱导鼻咽癌细胞发生上皮-间充质转化。
Oncol Res. 2019 Jul 12;27(7):801-807. doi: 10.3727/096504018X15446984186056. Epub 2019 Apr 12.
2
PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.PD-L1 通过 Ras 结合和 Ras/Erk/EMT 激活赋予胶质母细胞瘤多形性恶性肿瘤的特性。
Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1754-1769. doi: 10.1016/j.bbadis.2018.03.002. Epub 2018 Mar 3.
3
c-Src activation promotes nasopharyngeal carcinoma metastasis by inducing the epithelial-mesenchymal transition via PI3K/Akt signaling pathway: a new and promising target for NPC.c-Src激活通过PI3K/Akt信号通路诱导上皮-间质转化促进鼻咽癌转移:鼻咽癌的一个新的且有前景的靶点
Oncotarget. 2016 May 10;7(19):28340-55. doi: 10.18632/oncotarget.8634.
4
Inhibition of ZIP4 reverses epithelial-to-mesenchymal transition and enhances the radiosensitivity in human nasopharyngeal carcinoma cells.抑制 ZIP4 逆转人鼻咽癌细胞上皮间质转化并增强放射敏感性。
Cell Death Dis. 2019 Aug 5;10(8):588. doi: 10.1038/s41419-019-1807-7.
5
MicroRNA-192 promotes the development of nasopharyngeal carcinoma through targeting RB1 and activating PI3K/AKT pathway.MicroRNA-192 通过靶向 RB1 并激活 PI3K/AKT 通路促进鼻咽癌的发展。
World J Surg Oncol. 2020 Feb 3;18(1):29. doi: 10.1186/s12957-020-1798-y.
6
Lactoferrin mediates epithelial-mesenchymal transformation by regulating the PI3K/AKT/mTOR pathway to inhibit nasopharyngeal carcinoma metastasis.乳铁蛋白通过调节 PI3K/AKT/mTOR 通路介导上皮-间充质转化,抑制鼻咽癌转移。
Cell Mol Biol (Noisy-le-grand). 2024 Mar 31;70(3):130-135. doi: 10.14715/cmb/2024.70.3.19.
7
APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling.APLNR 参与 ATRA 诱导的鼻咽癌生长抑制,可能通过 PI3K-Akt-mTOR 信号通路抑制 EMT。
FASEB J. 2019 Nov;33(11):11959-11972. doi: 10.1096/fj.201802416RR. Epub 2019 Aug 13.
8
Epithelial cell adhesion molecule overexpression regulates epithelial-mesenchymal transition, stemness and metastasis of nasopharyngeal carcinoma cells via the PTEN/AKT/mTOR pathway.上皮细胞黏附分子过表达通过 PTEN/AKT/mTOR 通路调节鼻咽癌细胞的上皮-间充质转化、干性和转移。
Cell Death Dis. 2018 Jan 5;9(1):2. doi: 10.1038/s41419-017-0013-8.
9
miR-205-5p regulates epithelial-mesenchymal transition by targeting PTEN via PI3K/AKT signaling pathway in cisplatin-resistant nasopharyngeal carcinoma cells.miR-205-5p 通过靶向 PTEN 调控上皮-间充质转化及其 PI3K/AKT 信号通路在顺铂耐药鼻咽癌细胞中的作用。
Gene. 2019 Aug 20;710:103-113. doi: 10.1016/j.gene.2019.05.058. Epub 2019 May 31.
10
FOXD3 inhibits cell proliferation, migration, and invasion in nasopharyngeal carcinoma through regulation of the PI3K-Akt pathway.叉头框蛋白 D3 通过调控 PI3K-Akt 通路抑制鼻咽癌细胞增殖、迁移和侵袭。
Biochem Cell Biol. 2020 Dec;98(6):653-660. doi: 10.1139/bcb-2020-0011. Epub 2020 May 27.

引用本文的文献

1
TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives.TIM-3与PD-1在癌症免疫治疗中的协同作用:机制与展望。
Mol Biomed. 2025 May 7;6(1):27. doi: 10.1186/s43556-025-00267-6.
2
Epithelial-mesenchymal transition orchestrates tumor microenvironment: current perceptions and challenges.上皮-间质转化调控肿瘤微环境:当前认知与挑战
J Transl Med. 2025 Apr 2;23(1):386. doi: 10.1186/s12967-025-06422-5.
3
Therapeutic Applications of Programmed Death Ligand 1 Inhibitors in Small Cell Lung Cancer.程序性死亡配体1抑制剂在小细胞肺癌中的治疗应用

本文引用的文献

1
Targeted Disruption of miR-17-92 Impairs Mouse Spermatogenesis by Activating mTOR Signaling Pathway.靶向破坏miR-17-92通过激活mTOR信号通路损害小鼠精子发生。
Medicine (Baltimore). 2016 Feb;95(7):e2713. doi: 10.1097/MD.0000000000002713.
2
MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition.微小RNA-19引发肺癌细胞的上皮-间质转化并伴有生长抑制。
Lab Invest. 2015 Sep;95(9):1056-70. doi: 10.1038/labinvest.2015.76. Epub 2015 Jun 22.
3
Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
Biomedicines. 2025 Feb 7;13(2):401. doi: 10.3390/biomedicines13020401.
4
Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy.PD-1/PD-L1信号轴在肿瘤发生中的作用及其被生物活性天然化合物靶向用于癌症免疫治疗的研究
Mil Med Res. 2024 Dec 18;11(1):82. doi: 10.1186/s40779-024-00586-9.
5
The roles of PD-L1 in the various stages of tumor metastasis.PD-L1 在肿瘤转移的各个阶段中的作用。
Cancer Metastasis Rev. 2024 Dec;43(4):1475-1488. doi: 10.1007/s10555-024-10189-4. Epub 2024 May 11.
6
Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer.肿瘤细胞内在 PD-L1 信号诱导的上皮-间充质转化预测 PD-L1 高表达肺癌对免疫检查点抑制剂反应不良。
Br J Cancer. 2024 Jul;131(1):23-36. doi: 10.1038/s41416-024-02698-4. Epub 2024 May 10.
7
Integrative methylome and transcriptome analysis reveals epigenetic regulation of in laryngeal cancer.整合甲基化组和转录组分析揭示了喉癌中 的表观遗传调控。
Microb Genom. 2024 Mar;10(3). doi: 10.1099/mgen.0.001221.
8
Mesenchymal ovarian cancer cells promote CD8 T cell exhaustion through the LGALS3-LAG3 axis.间充质卵巢癌细胞通过 LGALS3-LAG3 轴促进 CD8 T 细胞衰竭。
NPJ Syst Biol Appl. 2023 Dec 12;9(1):61. doi: 10.1038/s41540-023-00322-4.
9
Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy.PD-L1 翻译后修饰的调控与肿瘤免疫治疗的进展。
Front Immunol. 2023 Jul 24;14:1230135. doi: 10.3389/fimmu.2023.1230135. eCollection 2023.
10
PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression.PD-1 独立于 PD-L1 在三阴性乳腺癌进展中的作用。
Int J Mol Sci. 2023 Mar 29;24(7):6420. doi: 10.3390/ijms24076420.
PD-1与PD-L1的共表达预示着鼻咽癌的不良预后。
Med Oncol. 2015 Mar;32(3):86. doi: 10.1007/s12032-015-0501-6. Epub 2015 Feb 22.
4
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.手术切除的非小细胞肺癌中 PD-L1 过表达与激活型 EGFR 突变的相关性。
Ann Oncol. 2014 Oct;25(10):1935-1940. doi: 10.1093/annonc/mdu242. Epub 2014 Jul 9.
5
MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA.微小RNA-122通过靶向RhoA触发间充质-上皮转化并抑制肝癌细胞的迁移和侵袭。
PLoS One. 2014 Jul 3;9(7):e101330. doi: 10.1371/journal.pone.0101330. eCollection 2014.
6
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.程序性死亡配体1(PD-L1)的表达与人类乳腺癌的不良预后相关。
Breast Cancer Res Treat. 2014 Jul;146(1):15-24. doi: 10.1007/s10549-014-2988-5. Epub 2014 May 20.
7
Programmed death ligand-1 expression in non-small cell lung cancer.程序性死亡配体-1 在非小细胞肺癌中的表达。
Lab Invest. 2014 Jan;94(1):107-16. doi: 10.1038/labinvest.2013.130. Epub 2013 Nov 11.
8
B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells.B7-H1 的表达与结直肠癌的预后不良相关,并调节 HCT116 结直肠癌细胞的增殖和侵袭。
PLoS One. 2013 Oct 4;8(10):e76012. doi: 10.1371/journal.pone.0076012. eCollection 2013.
9
Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma.局部晚期鼻咽癌放疗同期或序贯每周奥沙利铂增敏的 III 期临床研究长期随访结果
Ann Oncol. 2013 Aug;24(8):2131-6. doi: 10.1093/annonc/mdt163. Epub 2013 May 9.
10
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.抗 PD-1 和 B7-H1(PD-L1)抗体在治疗晚期人类癌症中的应用。
Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063.